TFOS DEWS II Management and Therapy Report

Lyndon Jones, Laura E. Downie, Donald Korb, Jose M. Benitez-del-Castillo, Reza Dana, Sophie X. Deng, Pham N. Dong, Gerd Geerling, Richard Yudi Hida, Yang Liu, Kyoung Yul Seo, Joseph Tauber, Tais H. Wakamatsu, Jianjiang Xu, James S. Wolffsohn, Jennifer P. Craig

Research output: Contribution to journalReview article

145 Citations (Scopus)

Abstract

The members of the Management and Therapy Subcommittee undertook an evidence-based review of current dry eye therapies and management options. Management options reviewed in detail included treatments for tear insufficiency and lid abnormalities, as well as anti-inflammatory medications, surgical approaches, dietary modifications, environmental considerations and complementary therapies. Following this extensive review it became clear that many of the treatments available for the management of dry eye disease lack the necessary Level 1 evidence to support their recommendation, often due to a lack of appropriate masking, randomization or controls and in some cases due to issues with selection bias or inadequate sample size. Reflecting on all available evidence, a staged management algorithm was derived that presents a step-wise approach to implementing the various management and therapeutic options according to disease severity. While this exercise indicated that differentiating between aqueous-deficient and evaporative dry eye disease was critical in selecting the most appropriate management strategy, it also highlighted challenges, based on the limited evidence currently available, in predicting relative benefits of specific management options, in managing the two dry eye disease subtypes. Further evidence is required to support the introduction, and continued use, of many of the treatment options currently available to manage dry eye disease, as well as to inform appropriate treatment starting points and understand treatment specificity in relation to dry eye disease subtype.

Original languageEnglish
Pages (from-to)575-628
Number of pages54
JournalOcular Surface
Volume15
Issue number3
DOIs
Publication statusPublished - 2017 Jul

Fingerprint

Eye Diseases
Therapeutics
Diet Therapy
Selection Bias
Complementary Therapies
Random Allocation
Tears
Sample Size
Anti-Inflammatory Agents

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

Jones, L., Downie, L. E., Korb, D., Benitez-del-Castillo, J. M., Dana, R., Deng, S. X., ... Craig, J. P. (2017). TFOS DEWS II Management and Therapy Report. Ocular Surface, 15(3), 575-628. https://doi.org/10.1016/j.jtos.2017.05.006
Jones, Lyndon ; Downie, Laura E. ; Korb, Donald ; Benitez-del-Castillo, Jose M. ; Dana, Reza ; Deng, Sophie X. ; Dong, Pham N. ; Geerling, Gerd ; Hida, Richard Yudi ; Liu, Yang ; Seo, Kyoung Yul ; Tauber, Joseph ; Wakamatsu, Tais H. ; Xu, Jianjiang ; Wolffsohn, James S. ; Craig, Jennifer P. / TFOS DEWS II Management and Therapy Report. In: Ocular Surface. 2017 ; Vol. 15, No. 3. pp. 575-628.
@article{2af7eac11ae64b76ae3ab55e5b3a6015,
title = "TFOS DEWS II Management and Therapy Report",
abstract = "The members of the Management and Therapy Subcommittee undertook an evidence-based review of current dry eye therapies and management options. Management options reviewed in detail included treatments for tear insufficiency and lid abnormalities, as well as anti-inflammatory medications, surgical approaches, dietary modifications, environmental considerations and complementary therapies. Following this extensive review it became clear that many of the treatments available for the management of dry eye disease lack the necessary Level 1 evidence to support their recommendation, often due to a lack of appropriate masking, randomization or controls and in some cases due to issues with selection bias or inadequate sample size. Reflecting on all available evidence, a staged management algorithm was derived that presents a step-wise approach to implementing the various management and therapeutic options according to disease severity. While this exercise indicated that differentiating between aqueous-deficient and evaporative dry eye disease was critical in selecting the most appropriate management strategy, it also highlighted challenges, based on the limited evidence currently available, in predicting relative benefits of specific management options, in managing the two dry eye disease subtypes. Further evidence is required to support the introduction, and continued use, of many of the treatment options currently available to manage dry eye disease, as well as to inform appropriate treatment starting points and understand treatment specificity in relation to dry eye disease subtype.",
author = "Lyndon Jones and Downie, {Laura E.} and Donald Korb and Benitez-del-Castillo, {Jose M.} and Reza Dana and Deng, {Sophie X.} and Dong, {Pham N.} and Gerd Geerling and Hida, {Richard Yudi} and Yang Liu and Seo, {Kyoung Yul} and Joseph Tauber and Wakamatsu, {Tais H.} and Jianjiang Xu and Wolffsohn, {James S.} and Craig, {Jennifer P.}",
year = "2017",
month = "7",
doi = "10.1016/j.jtos.2017.05.006",
language = "English",
volume = "15",
pages = "575--628",
journal = "Ocular Surface",
issn = "1542-0124",
publisher = "Ethis Communications, Inc.",
number = "3",

}

Jones, L, Downie, LE, Korb, D, Benitez-del-Castillo, JM, Dana, R, Deng, SX, Dong, PN, Geerling, G, Hida, RY, Liu, Y, Seo, KY, Tauber, J, Wakamatsu, TH, Xu, J, Wolffsohn, JS & Craig, JP 2017, 'TFOS DEWS II Management and Therapy Report', Ocular Surface, vol. 15, no. 3, pp. 575-628. https://doi.org/10.1016/j.jtos.2017.05.006

TFOS DEWS II Management and Therapy Report. / Jones, Lyndon; Downie, Laura E.; Korb, Donald; Benitez-del-Castillo, Jose M.; Dana, Reza; Deng, Sophie X.; Dong, Pham N.; Geerling, Gerd; Hida, Richard Yudi; Liu, Yang; Seo, Kyoung Yul; Tauber, Joseph; Wakamatsu, Tais H.; Xu, Jianjiang; Wolffsohn, James S.; Craig, Jennifer P.

In: Ocular Surface, Vol. 15, No. 3, 07.2017, p. 575-628.

Research output: Contribution to journalReview article

TY - JOUR

T1 - TFOS DEWS II Management and Therapy Report

AU - Jones, Lyndon

AU - Downie, Laura E.

AU - Korb, Donald

AU - Benitez-del-Castillo, Jose M.

AU - Dana, Reza

AU - Deng, Sophie X.

AU - Dong, Pham N.

AU - Geerling, Gerd

AU - Hida, Richard Yudi

AU - Liu, Yang

AU - Seo, Kyoung Yul

AU - Tauber, Joseph

AU - Wakamatsu, Tais H.

AU - Xu, Jianjiang

AU - Wolffsohn, James S.

AU - Craig, Jennifer P.

PY - 2017/7

Y1 - 2017/7

N2 - The members of the Management and Therapy Subcommittee undertook an evidence-based review of current dry eye therapies and management options. Management options reviewed in detail included treatments for tear insufficiency and lid abnormalities, as well as anti-inflammatory medications, surgical approaches, dietary modifications, environmental considerations and complementary therapies. Following this extensive review it became clear that many of the treatments available for the management of dry eye disease lack the necessary Level 1 evidence to support their recommendation, often due to a lack of appropriate masking, randomization or controls and in some cases due to issues with selection bias or inadequate sample size. Reflecting on all available evidence, a staged management algorithm was derived that presents a step-wise approach to implementing the various management and therapeutic options according to disease severity. While this exercise indicated that differentiating between aqueous-deficient and evaporative dry eye disease was critical in selecting the most appropriate management strategy, it also highlighted challenges, based on the limited evidence currently available, in predicting relative benefits of specific management options, in managing the two dry eye disease subtypes. Further evidence is required to support the introduction, and continued use, of many of the treatment options currently available to manage dry eye disease, as well as to inform appropriate treatment starting points and understand treatment specificity in relation to dry eye disease subtype.

AB - The members of the Management and Therapy Subcommittee undertook an evidence-based review of current dry eye therapies and management options. Management options reviewed in detail included treatments for tear insufficiency and lid abnormalities, as well as anti-inflammatory medications, surgical approaches, dietary modifications, environmental considerations and complementary therapies. Following this extensive review it became clear that many of the treatments available for the management of dry eye disease lack the necessary Level 1 evidence to support their recommendation, often due to a lack of appropriate masking, randomization or controls and in some cases due to issues with selection bias or inadequate sample size. Reflecting on all available evidence, a staged management algorithm was derived that presents a step-wise approach to implementing the various management and therapeutic options according to disease severity. While this exercise indicated that differentiating between aqueous-deficient and evaporative dry eye disease was critical in selecting the most appropriate management strategy, it also highlighted challenges, based on the limited evidence currently available, in predicting relative benefits of specific management options, in managing the two dry eye disease subtypes. Further evidence is required to support the introduction, and continued use, of many of the treatment options currently available to manage dry eye disease, as well as to inform appropriate treatment starting points and understand treatment specificity in relation to dry eye disease subtype.

UR - http://www.scopus.com/inward/record.url?scp=85025642128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025642128&partnerID=8YFLogxK

U2 - 10.1016/j.jtos.2017.05.006

DO - 10.1016/j.jtos.2017.05.006

M3 - Review article

C2 - 28736343

AN - SCOPUS:85025642128

VL - 15

SP - 575

EP - 628

JO - Ocular Surface

JF - Ocular Surface

SN - 1542-0124

IS - 3

ER -

Jones L, Downie LE, Korb D, Benitez-del-Castillo JM, Dana R, Deng SX et al. TFOS DEWS II Management and Therapy Report. Ocular Surface. 2017 Jul;15(3):575-628. https://doi.org/10.1016/j.jtos.2017.05.006